Pharvaris NV is a pharmaceutical firm acclaimed for its innovative approach to treating Hereditary Angioedema (HAE), which impacts thousands of people globally. Embedding transformational science in its operations, it operates primarily in the United States and Europe, catering to a diverse population.
Pharvaris operates in the pharmaceutical industry, which is an essential part of the healthcare sector. It provides innovative drug advancements focused primarily on B2-receptor antagonist small molecules for the treatment of bradykinin-mediated diseases.
Keep up to date on the latest share price changes by adding PHVS stock to your eToro watchlist.